FDA-approved HCV Treatments

PegIntron plus Ribavirin

Pegasys plus Ribavirin



PegIntron plus Ribavirin

•PegIntron plus Ribavirin in HCV Genotype 1 Patients with Slow Virological Response: Analysis of Early Enrollers in the SUCCESS Study
•Consistent SVR Rates across All Weight Categories in the Canadian POWeR Program
•A la Carte Therapy More Cost-effective than Standard Combination Therapy for Treatment-naive Patients with Chronic Hepatitis C
•Treatment Extension to 72 Weeks of PegIntron plus Weight-based Ribavirin Improves SVR Rates in Difficult-to-Treat Slow Responders with Genotype 1
•HCV RNA Negativity after 12 Weeks of Therapy Is the Best Predictor of SVR in Re-Treatment of Non-Responders: The EPIC3 Program
•Response to PegIntron and Ribavirin in HCV Patients with Body Weight >125 kg: the WIN-R Trial
•Risk Factors for Relapse in Patients with High Viral Load and Genotype 3 Hepatitis C in the WIN-R Trial
•PegIntron and Ribavirin Are Equally Effective and Well Tolerated in Patients >65 Years Old in Comparison to Other Age Groups: WIN-R Trial
•Sustained Virological Response to PegIntron Plus Ribavirin in Asian and Hispanic Patients


Pegasys plus Ribavirin

•Utility of Virological Response at Weeks 4 and 12 in the Prediction of SVR in Genotype 2/3 Patients: ACCELERATE Trial Results
•More Frequent Dosing of Pegasys/Ribavirin Improves SVR Rate in Prior Non-responder Genotype 1 HCV Patients with Severe Fibrosis
•Baseline HCV RNA Level of 400,000 Is Optimal Cut-off Point to Differentiate Low and High Probability of SVR
•Early Predictors of Anemia in Genotype 1 HCV Patients Treated with Pegasys plus Ribavirin
•Pegasys plus Ribavirin for 16 versus 24 Weeks in Patients with HCV Genotype 2
•In ACCELERATE Trial, Highest SVR Seen in Patients Who Received the Longest Duration of Therapy with Pegasys and the Highest Mean Dose of Ribavirin Based on Body Weight
•Positive Impact of Higher Ribavirin Doses and Longer Duration of Therapy with Pegasys plus Ribavirin in HIV/HCV Coinfected Patients: The PRESCO Trial
•Higher Fixed Doses of Both Pegasys and Ribavirin May Benefit "Difficult-to-Cure" Genotype 1 Patients with High Viral Load and Above Average Body Weight
•Baseline HCV RNA of 400,000 Best Predicts SVR and Relapse Rates in Patients Treated with Pegasys plus Ribavirin





Google_______________


 

 

 

 

 

 

 

 

 

 

 

 


Conference
Main Page

Hepatitis C
FDA-Approved
Treatments

Monotherapies
Intron A
Roferon
Infergen
Pegasys
PEG-Intron

Combination
 Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Hepatitis B
FDA-Approved
Treatments

Baraclude
 Epivir-HBV
 Hepsera
 Intron A
 Pegasys
 Tyzeka